Bellerophon Therapeutics Announces FDA Clears Initiation of Phase 3 Study for INOpulse® Inhaled Nitric Oxide Therapy to Treat COVID-19

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement

Daniel Sontupe
Market Access

Paul Theisen
Patient Acquisition

Frank Burrell
Scientific Storytelling

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing

Pat Purcell
Meeting Engagement

Suma Ramadas, PhD
Medical Affairs

Matthew Durham
Omnidynamic Marketing

Joey Cohen
Medication Adherence

Matt Turner
Patient Affordability